Compare Travere Therapeutics Inc. Common Stock (TVTX) vs Vital Farms Inc (VITL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs Vital Farms Inc — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B), while Vital Farms Inc trades at $8.92 (market cap $400.98M). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 12.2× Vital Farms Inc's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, Vital Farms Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and Vital Farms Inc for 15 Days on average.
| TVTX | VITL | |
|---|---|---|
Market Cap | $4.88B | $400.98M |
Volume | 1,668,577 | 1,181,598 |
Sector | Health | Consumer Staples |
52-Week High | $67.52 | $40.85 |
52-Week Low | $26.79 | $8.28 |
Typical Hold Time | 0 Days | 15 Days |
Enterprise Value | $5.01B | $487.99M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Vital Farms (VITL) trades at $9.34, down 1.37% amid bearish technical signals and challenging fundamentals. The stock faces pressure from declining earnings, with Q1 2026 missing expectations and Q3 2026 expected at -$0.13 EPS. Despite a 56% analyst buy rating and $13.11 consensus target, recent news highlights strategic review discussions and pricing pressures in the egg market. Revenue remains flat at $766M for 2026 with net margins collapsing to near-zero, while cash flow trends show significant operational challenges.
The outlook remains cautious with near-term headwinds from industry oversupply and margin compression. Investment opportunity exists if strategic options materialize, but risks include sustained profitability challenges and competitive pressures. Current valuation metrics suggest potential upside if execution improves, but investors should monitor Q3 earnings and strategic developments closely.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About Vital Farms Inc
Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →
